IBD Research Resource Center

Drug ID:	Drug11
Drug Name:	Berberine
CID:	2353
DrugBank ID:	DB04115
Modality:	Small Molecule
Groups:	experimental
US Approved:	NO
Other Approved:	NO
Identifier:	NCT02962245
Molecular Formula:	C20H18NO4+
Molecular Weight:	336.4 g/mol
Isomeric SMILES:	COC1=C(C2=C[N+]3=C(C=C2C=C1)C4=CC5=C(C=C4CC3)OCO5)OC
Synonyms:	berberine; 2086-83-1; Umbellatine; Berberin; Berbericine; Majarine; Thalsine; Umbellatin; Berberone; Benzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium, 5,6-dihydro-9,10-dimethoxy-
Phase 0:	2
Phase 1:	4
Phase 2:	15
Phase 3:	15
Phase 4:	21
Description:	An alkaloid from Hydrastis canadensis L., Berberidaceae. It is also found in many other plants. It is relatively toxic parenterally, but has been used orally for various parasitic and fungal infections and as antidiarrheal. [PubChem]

Molecular Structure

Knowledge Graph

dtID	CID	Compound Name	Gene ID	Gene Name	Species	PubMed IDs	Action
dt90	2353	Berberine	7124	TNF	Rattus norvegicus (Norway rat)	25600690	Berberine inhibits the reaction [mercuric chloride results in increased expression of TNF protein]
dt91	2353	Berberine	7150	TOP1	Homo sapiens (human)	23747414	Berberine results in decreased activity of TOP1 protein
dt92	2353	Berberine	7153	TOP2A	Homo sapiens (human)	23747414	TOP2A protein affects the susceptibility to berberine\|top2a protein affects the reaction [berberine results in increased expression of H2AX protein modified form]
dt93	2353	Berberine	7157	TP53	Homo sapiens (human)	26712469	Berberine results in increased phosphorylation of and results in increased acetylation of TP53 protein\|[berberine co-treated with niacinamide] results in increased expression of and results in increased acetylation of TP53 protein
dt94	2353	Berberine	7157	TP53	Homo sapiens (human)	20656010	Berberine results in increased expression of TP53 mrna\|berberine results in increased expression of TP53 protein
dt95	2353	Berberine	7186	TRAF2	Mus musculus (house mouse)	30240693	Berberine inhibits the reaction [[lipopolysaccharide, escherichia coli O111 B4 co-treated with TNF protein] results in increased secretion of TRAF2 protein]\|berberine inhibits the reaction [[lipopolysaccharide, escherichia coli O111 B4 co-treated with TNF
dt96	2353	Berberine	6737	TRIM21	Homo sapiens (human)	36822301	Berberine promotes the reaction [IGF2BP3 protein binds to TRIM21 protein]
dt97	2353	Berberine	100131187	TSTD1	Homo sapiens (human)	27311644	Berberine results in increased expression of TSTD1 mRNA
dt98	2353	Berberine	7319	UBE2A	Homo sapiens (human)	27311644	Berberine results in decreased expression of UBE2A mRNA
dt99	2353	Berberine	7320	UBE2B	Homo sapiens (human)	27311644	Berberine results in decreased expression of UBE2B mRNA

No data available

Phase Distribution

Phase Description

Phase 0: Exploratory trials to assess drug behavior in humans
Phase 1: Safety trials to determine safe dosage range
Phase 2: Efficacy trials to evaluate therapeutic effects
Phase 3: Large-scale trials to confirm efficacy and safety
Phase 4: Post-marketing surveillance for long-term safety and efficacy

Trial ID	Title	Phase	Status	Sponsor	Indications	Interventions
NCT02962245	Efficacy of Treatment With Berberine to Maintain Remission in Ulcerative Colitis	PHASE4	WITHDRAWN	Xijing Hospital of Digestive Diseases	Ulcerative Colitis	DRUG: berberine\|DRUG: regular treatment	Details
NCT02365480	Berberine Chloride in Preventing Colorectal Cancer in Patients With Ulcerative Colitis in Remission	PHASE1	COMPLETED	National Cancer Institute (NCI)	Ulcerative Colitis	DRUG: Berberine Chloride\|OTHER: Laboratory Biomar…	Details
ChiCTR2400083224	A clinical trial to evaluate the relationship between nitric oxide content in type 3 natural lymphocytes and severity of enteritis and response to drug intervention in patients with inflammatory bowel disease	NULL	Not Recruiting	Peking University Third Hospital	Inflammatory Bowel Disease	Trial group:Berberine hydrochloride tablets mesa…	Details
NCT06187298	Effect of Oral Combined Berberine and Curcumin Pharmacological Therapy on IBS	NULL	COMPLETED	Liaquat University of Medical & Health Sciences	Irritable Bowel Syndrome	DIETARY_SUPPLEMENT: A combined supplement of Berb…	Details
NCT05707429	Sexual Function and Quality of Life Among Patients Suffering From Inflammatory Bowel Disease(Inactive Stage)	NULL	COMPLETED	Assiut University	Sexual Function Disturbances\|Inflammatory Bowel D…	OTHER: The Arabic version of The International In…	Details
NCT05701501	Clinical Study of Vitamin B5 in Adjuvant Treatment of IBD	NA	UNKNOWN	Changhai Hospital	Inflammatory Bowel Diseases	DRUG: Vitamin B5 Tablets\|DRUG: placebo	Details
NCT05688852	VTX958 for the Treatment of Moderately to Severely Active Crohn's Disease	PHASE2	TERMINATED	Ventyx Biosciences, Inc	Crohn Disease	DRUG: VTX958\|DRUG: VTX958\|DRUG: VTX958 Placebo	Details
NCT05687474	Baby Detect : Genomic Newborn Screening	NULL	COMPLETED	Centre Hospitalier Universitaire de Liege	Congenital Adrenal Hyperplasia\|Familial Hyperinsu…	None	Details
NCT05684484	Role of Roflumilast in Ulcerative Colitis	PHASE4	COMPLETED	Tanta University	Ulcerative Colitis	DRUG: Roflumilast 500 MCG Oral Tablet [DALIRESP]\|…	Details
NCT05668013	A Study to Evaluate the Long-Term Effect of TEV-48574 in Moderate to Severe Ulcerative Colitis or Crohn's Disease	PHASE2	ACTIVE_NOT_RECRUITING	Teva Branded Pharmaceutical Products R&D LLC	Crohn Disease\|Colitis, Ulcerative	DRUG: TEV-48574 Dose Regimen A\|DRUG: TEV-48574 Do…	Details
NCT05666960	R-3750 in Patients With Mild to Moderate Ulcerative Colitis	PHASE1	RECRUITING	Rise Therapeutics LLC	Ulcerative Colitis Chronic Mild\|Ulcerative Coliti…	DRUG: R-3750	Details
NCT05663671	Evaluate Established Anti-DEFA5 mAbs Diagnostic Efficacy and Safety in IBD	NULL	UNKNOWN	Meharry Medical College	Inflammatory Bowel Diseases\|Ulcerative Colitis\|Cr…	DIAGNOSTIC_TEST: Diagnostic Test	Details
NCT05659953	LMT503 First-in-human SAD, MAD, and FE Study	PHASE1	NOT_YET_RECRUITING	Lmito Therapeutics Inc.	Inflammatory Bowel Disease\|Colitis, Ulcerative\|Cr…	DRUG: LMT503\|DRUG: Placebo	Details
NCT05643534	Study to Assess Safety and Efficacy of Tenapanor for Treatment of IBS-C in Pediatric Patients 12 to Less Than 18 Years	PHASE3	RECRUITING	Ardelyx	Irritable Bowel Syndrome With Constipation (IBS-C)	DRUG: Tenapanor 50 MG\|DRUG: Tenapanor 25 mg bid\|D…	Details
NCT05638347	A Trial of HRS-7085 Tablet in Healthy Participants With and Without Food Effect.	PHASE1	COMPLETED	Atridia Pty Ltd.	Inflammatory Bowel Disease	DRUG: HRS-7085 tablets\|DRUG: Placebo tablet	Details
NCT05624801	Cholecalciferol Comedication in Patients With Chronic Inflammatory Bowel Diseases (Crohn's Disease or Ulcerative Colitis) - the 5C-study	PHASE3	Recruiting	University Hospital, Basel, Switzerland	IBD	Drug: D3 VitaCaps	Details
NCT07168434	Saccharomyces Boulardii CNCM I-745 in Irritable Bowel Syndrome	PHASE3	RECRUITING	Biocodex	IBS (Irritable Bowel Syndrome)\|IBS-D (Diarrhea-pr…	DRUG: Saccharomyces Boulardii 250 MG\|DRUG: Placeb…	Details
NCT05611671	A Study to Evaluate MORF-057 in Adults With Moderately to Severely Active UC	PHASE2	ACTIVE_NOT_RECRUITING	Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)	Inflammatory Bowel Diseases\|Colitis, Ulcerative	DRUG: MORF-057\|DRUG: Placebo	Details
NCT05549323	A Study to Learn About the Safety, Effects and Pharmacokinetics of Study Medication (PF-07054894) for the Treatment of Ulcerative Colitis	PHASE1	TERMINATED	Pfizer	Ulcerative Colitis	DRUG: PF-07054894\|DRUG: Placebo	Details
NCT07161297	Remimazolam for Colonoscopy in IBD Patients	PHASE4	NOT_YET_RECRUITING	Humanitas Clinical and Research Center	IBD (Inflammatory Bowel Disease)	DRUG: Intravenous remimazolam (5 mg initially, wi…	Details

Disease ID	Disease Name	Definition	Category	Related Drugs	Mechanism
No data available

Strategy ID	Therapeutic Strategy	Synonyms	Related Drugs	Mechanism
S01	Anti-inflammatory	inflammatory	5-Aminosalicylates (5-ASAs); corticosteroids	Crohn's disease and ulcerative colitis are the two main com…	Details
S06	Anti-fibrosis	fibrosis; tissue remodelling	GS-5745; STNM01	Tissue remodelling and destruction in patients with IBD is …	Details
S07	Blockade of cytokine	Cytokine signalling	apremilast; roflumilast; filgotinib; tofacitinib; ABT494; ABT-874; ustekinumab; isankizumab; LY-2525623; AMG139; MEDI2079; guselkumab	Various T-cell subsets, their differentiation pathways and …	Details